Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials

Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculos...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacol Ther
Main Authors: Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5545752/
https://ncbi.nlm.nih.gov/pubmed/28124478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.634
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares